Skip To Main Content
John Sharp on Muck Rack

John Sharp

Cleveland
As seen in: LinkedIn, Nature, Wiley Online Library, Healthcare IT News, MDEdge, The Journal Record, INDVSTRVS
Adjunct Faculty, Health Informatics, Kent State University. Interests: #digitalhealth and Clinical analytics. Views expressed are my own.
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with John

Contact John, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Real-world outcomes of bispecific antibody therapy after chimeric antigen receptor T-cell therapy in follicular lymphoma

|
By John Sharp, Subodh Bhatta, Jennifer Huang, Colin Thomas Verified, Omar Elghawy, Lindsey A. Fitzgerald, Daniel Reef, Timothy Voorhees, Supriya Gupta, Natalie Grover Verified, Stefan K. Barta, Mazyar Shadman, Narendranath Epperla, Andinet Teferra
| Nature Verified
Dear Editor, Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, with approximately 14,000 new diagnoses annually in the United States. Although FL has historically been considered incurable, front-line therapy can induce durable remissions. Nevertheless, up to 50% of patients require multiple lines of treatment [1].
Open in Who Shared Issue with article?

Cutaneous adverse events following CAR T-cell therapy in hematologic malignancies

|
By Elvira R Umyarova, John Sharp, Qiuhong Zhao, Nathan M. Denlinger, Timothy Voorhees, Marcos de Lima, Narendranath Epperla, Charles Pei, William Pellegrino
| Nature Verified
To the Editor Chimeric antigen receptor (CAR) T-cell therapy has transformed outcomes for patients with relapsed or refractory (R/R) hematologic malignancies [1], particularly diffuse large B-cell lymphoma (DLBCL), mantle cell lymphoma (MCL), and B-acute lymphoblastic leukemia (B-ALL). While cytokine release syndrome and neurotoxicity are well-characterized toxicities of CAR T-cell therapy, data on associated cutaneous adverse events (AEs) are limited [2,3,4].
Open in Who Shared Issue with article?

Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma

|
By John Sharp, Qiuhong Zhao, Timothy Voorhees, David Bond
| Wiley Online Library Verified
INTRODUCTION Chimeric antigen receptor T-cell (CAR-T) therapy revolutionized the treatment of relapsed/refractory large B-cell lymphomas (LBCL)1-5 and was approved in this setting.6 It has unique toxicities, including cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity (ICANS).7 Acute kidney injury (AKI), an abrupt decrease in renal function causing dysregulation of extracellular volume, electrolytes and nitrogenous waste products, is an increasingly recognized...
Open in Who Shared Issue with article?
See all 33 articles